10-Q · May 12, 2026
SELLAS Life Sciences Group reported no revenue for Q1 2026, with a net loss of $8.4 million, worsening from a $5.8 million loss in Q1 2025. Operating expenses increased by $3.2 million due to higher R&D and…
Earnings analysis · 10-Q
SLS earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include the financial statements, MD&A, balance sheet, cash-flow statement, or segment disclosures, so margin, liquidity, working-capital, and cash-flow trends cannot be assessed from the…
Read full summary
The supplied 10-Q text does not include the financial statements, MD&A, balance sheet, cash-flow statement, or segment disclosures, so margin, liquidity, working-capital, and cash-flow trends cannot be assessed from the filing extract. Reported quarterly EPS was -$0.02 versus -$0.07 in Q2 2025 and -$0.05 in Q1 2026, while reported revenue was $0.0. The principal filing development is negative: the 3D Medicines arbitration claims were dismissed and SELLAS was allocated approximately $1.0 million of legal fees and costs; no quantitative guidance was provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.02
What stood out
-
Disclosure controls remained effective
The filing reports that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance that required information was reported on time.
-
No material control changes
The company reported no change in internal control over financial reporting during the quarter ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, those controls.
-
Three tax-related trading plans adopted
Three directors adopted Rule 10b5-1 plans covering up to an aggregate 45,000 shares, intended to satisfy tax obligations arising from vesting restricted stock units.
What to watch
-
3D Medicines claims dismissed
The sole arbitrator dismissed SELLAS’s claims against 3D Medicines in July 2026. The claims included milestone payments, including two expected development milestones totaling $13.0 million.
-
Approximately $1.0M legal-cost allocation
The arbitrator administratively allocated approximately $1.0 million of 3D Medicines’ legal fees and costs to SELLAS, creating an additional cash expense.
-
Development in China remains unresolved
The dismissed arbitration involved 3D Medicines’ failure to use commercially reasonable best efforts to develop GPS in the 3DMed Territory, particularly mainland China; the filing states approximately 20 patients were expected to participate from mainland China.
Management's outlook
The 10-Q provides no quantitative revenue, EPS, operating, or cash-flow guidance; outlook was not provided in the filing.
Earlier filings 4
10-K · March 19, 2026
SELLAS Life Sciences Group, Inc. reported a net loss of $26.9 million and no revenue for the year ended December 31, 2025. The company experienced a decrease in R&D expenses primarily attributed to trial completion. As…
10-Q · November 12, 2025
SELLAS Life Sciences Group, Inc. reported a net loss of $6.8 million in Q3 2025, reflecting a slight improvement compared to $7.1 million in the prior year. The company continues to report no revenue generation during…
10-Q · August 12, 2025
SELLAS Life Sciences Group, Inc. reported its Q2 2025 results, with consistent losses reflected in an EPS loss of -$0.07, in line with the prior quarter. Revenue remained at $0.0, similar to previous quarters, while…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.